| Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo A Chaturvedi, L Herbst, S Pusch, L Klett, R Goparaju, D Stichel, ... Leukemia 31 (10), 2020, 2017 | 136 | 2017 |
| Linking aberrant chromatin features in chronic lymphocytic leukemia to transcription factor networks JP Mallm, M Iskar, N Ishaque, LC Klett, SJ Kugler, JM Muino, VB Teif, ... Molecular Systems Biology 15 (5), e8339, 2019 | 51 | 2019 |
| Genome-scale reconstruction of the Streptococcus pyogenes M49 metabolic network reveals growth requirements and indicates potential drug targets J Levering, T Fiedler, A Sieg, KWA van Grinsven, S Hering, N Veith, ... Journal of biotechnology 232, 25-37, 2016 | 28 | 2016 |
| Methylome-based cell-of-origin modeling (Methyl-COOM) identifies aberrant expression of immune regulatory molecules in CLL JA Wierzbinska, R Toth, N Ishaque, K Rippe, JP Mallm, LC Klett, ... Genome medicine 12 (1), 1-19, 2020 | 17 | 2020 |
| Pan-Mutant-IDH1 Inhibitor Bay-1436032 Is Highly Effective Against Human IDH1 Mutant Acute Myeloid Leukemia In Vivo M Heuser, L Herbst, S Pusch, L Klett, R Goparaju, D Stichel, S Kaulfuss, ... Blood, The Journal of the American Society of Hematology 128 (22), 745-745, 2016 | 8 | 2016 |
| Dissecting Heterogeneity of Tumor Cells and Their Microenvironment in Refractory Multiple Myeloma SM Tirier, JP Mallm, N Casiraghi, H Susak, N Giesen, AM Poos, K Bauer, ... Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019 | | 2019 |
